The supportive role of intranasal mometasone furoate in controlling bronchial asthma Review article

Abstract

Bronchial asthma and allergic rhinitis are chronic inflammatory diseases of the respiratory system with a common immunological ground based on the predominance of the Th2 response. The presence of allergic rhinitis significantly increases the risk of developing bronchial asthma, and the coexistence of these two conditions adversely affects symptom control, exacerbation frequency, and quality of life of patients. Contemporary pathophysiological concepts assume the existence of a close functional and immunological relationship between the upper and lower respiratory tract. Chronic inflammation in the nose can initiate and sustain an inflammatory response in the bronchi, thereby worsening the course of allergic rhinitis.

Mometasone furoate, a new-generation intranasal glucocorticosteroid, has a strong anti-inflammatory effect with minimal systemic bioavailability. It inhibits key inflammatory cytokines (IL-4, IL-5, IL-13), reduces eosinophil infiltration, and improves nasal mucosal function. Numerous studies have shown that its use in patients with allergic rhinitis and concomitant bronchial asthma improves respiratory parameters, reduces asthma symptoms, decreases the need for as-needed medication, and improves quality of life.

The article reviews current data on the supportive role of mometasone furoate in the treatment of bronchial asthma in the context of integrated care. The importance of early intervention, especially in children, is also emphasized in the context of the possible impact of chronic nasal obstruction on the morphological development of the facial skeleton.